Klinische Pädiatrie, Inhaltsverzeichnis Klin Padiatr 2020; 232(02): 82DOI: 10.1055/s-0040-1701820 S-II Session II: Immune Checkpoint Inhibition and Drug Targets © Georg Thieme Verlag KG Stuttgart · New YorkBrentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma Authors Institutsangaben J Hochberg 1 Pediatrics, New York Medical College, Valhalla, USA J Basso 1 Pediatrics, New York Medical College, Valhalla, USA L Klejmont 1 Pediatrics, New York Medical College, Valhalla, USA A Flower 1 Pediatrics, New York Medical College, Valhalla, USA K Bortfeld 1 Pediatrics, New York Medical College, Valhalla, USA L Harrison 1 Pediatrics, New York Medical College, Valhalla, USA Q Shi 2 Statistics, New York Medical College, Valhalla, USA H Islam 3 Pathology, New York Medical College, Valhalla, USA P Gerard 4 Radiology, New York Medical College, Valhalla, USA S Voss 5 Radiology, Boston Children’s Hospital, Boston, USA M Cairo 1 Pediatrics, New York Medical College, Valhalla, USA Artikel empfehlen Abstract Volltext Referenzen References 1 Hochberg J, Goldman S and, Cairo M.S. Lymphoma. . Chapter 496 in: Kliegman RM. (editor), Nelson Textbook of Pediatrics. , 21st Edition,. 2019. . 2 Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012; Jun 20; 30: 2183-9 . 3 Yvette L. Kasamon, Heather A. Jacene, Christopher D. Gocke, Lode J. Swinnen, Douglas E. Gladstone, Brandy Perkins, Brian K. Link, Leslie L. Popplewell, Thomas M. Habermann, Joseph M. Herman, William H. Matsui, Richard J. Jones, Richard F. Ambinder. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012; May 3; 119 (18) ) : 4129-4132 .
